ArticleJournal of medical case reports2026
Competing therapy options for severe amlodipine poisoning-lessons learned: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe report two cases of severe amlodipine poisoning (> 1000 mg) during a suicide attempt. CASE PRESENTATION: Both patients (male, white, aged 70 and 28 years, respectively) experienced severe vasoplegic shock and were referred to us from regional hospitals via our extracorporeal membrane oxygenation hotline. In addition to the recommended therapy, both patients underwent albumin dialysis. Despite this, the vasopressor demand remained sky high, in both cases above 2 µg/kg/minute norepinephrine. Ultimately, both patients required veno-arterial extracorporeal membrane oxygenation support. There were slight differences in treatment; one patient received lipid emulsion and the other hydroxycobalamin, both of which caused interesting technical difficulties with continuous renal replacement therapy. Finally, we were able to wean both patients off extracorporeal support as well as all vasopressors. Both were discharged from the intensive care unit.
conclusionIn cases so severe, swift action is of the essence and some of the available treatments cancel each other out and should be timed accordingly. Therefore, on the basis of our experiences and the standing recommendations we developed a treatment algorithm that takes not only the case severity but also the time frame in which the treatment should be administered into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.